• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Next-Generation Sequencing Identified a Novel Crizotinib-Sensitive PLB1-ALK Rearrangement in Lung Large-Cell Neuroendocrine Carcinoma.

作者信息

Wang Shuai, Wu Xuan, Zhao Jiuzhou, Chen Haiyang, Zhang Zhe, Wang Mingyue, Xu Cong, Wang Yongsen, Wang Lili, He Zhen, Wang Qiming

机构信息

Department of Internal Medicine, Henan Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou, PR China.

Department of Molecular Pathology, Henan Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou, PR China.

出版信息

Clin Lung Cancer. 2021 May;22(3):e366-e370. doi: 10.1016/j.cllc.2020.05.026. Epub 2020 Jun 2.

DOI:10.1016/j.cllc.2020.05.026
PMID:32651063
Abstract
摘要

相似文献

1
Next-Generation Sequencing Identified a Novel Crizotinib-Sensitive PLB1-ALK Rearrangement in Lung Large-Cell Neuroendocrine Carcinoma.下一代测序在肺大细胞神经内分泌癌中鉴定出一种新型的对克唑替尼敏感的PLB1-ALK重排。
Clin Lung Cancer. 2021 May;22(3):e366-e370. doi: 10.1016/j.cllc.2020.05.026. Epub 2020 Jun 2.
2
Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib.伴有间变性淋巴瘤激酶（ALK）重排且对阿来替尼有反应的大细胞神经内分泌癌
Intern Med. 2018 Mar 1;57(5):713-716. doi: 10.2169/internalmedicine.9368-17. Epub 2017 Nov 20.
3
Use of ALK Immunohistochemistry for Optimal Therapeutic Strategy of Pulmonary Large-cell Neuroendocrine Carcinoma and Identification of a Novel Fusion Oncokinase.ALK免疫组化在肺大细胞神经内分泌癌最佳治疗策略中的应用及一种新型融合癌激酶的鉴定
Anticancer Res. 2019 Jan;39(1):413-420. doi: 10.21873/anticanres.13127.
4
Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient.下一代测序揭示了一种新型的 ALK G1128A 突变，该突变对 ALK 重排 NSCLC 患者的克唑替尼耐药。
Lung Cancer. 2018 Sep;123:83-86. doi: 10.1016/j.lungcan.2018.07.004. Epub 2018 Jul 6.
5
A case of large-cell neuroendocrine carcinoma harboring an EML4-ALK rearrangement with resistance to the ALK inhibitor crizotinib.一例伴有EML4-ALK重排且对ALK抑制剂克唑替尼耐药的大细胞神经内分泌癌病例。
J Thorac Oncol. 2014 Jun;9(6):e40-2. doi: 10.1097/JTO.0000000000000103.
6
Heterogeneous Tumor-Immune Microenvironments between Primary and Metastatic Tumors in a Patient with Rearrangement-Positive Large Cell Neuroendocrine Carcinoma.一名伴有基因重排阳性的大细胞神经内分泌癌患者的原发灶与转移灶之间存在异质性肿瘤-免疫微环境。
Int J Mol Sci. 2020 Dec 19;21(24):9705. doi: 10.3390/ijms21249705.
7
CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.CUX1-ALK，一种新的 ALK 重排，对非小细胞肺癌的克唑替尼有反应。
J Thorac Oncol. 2018 Nov;13(11):1792-1797. doi: 10.1016/j.jtho.2018.07.008. Epub 2018 Aug 7.
8
Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib.携带表皮生长因子受体（EGFR）突变且对吉非替尼敏感的肺大细胞神经内分泌癌
J Clin Oncol. 2011 Dec 1;29(34):e819-22. doi: 10.1200/JCO.2011.36.2251. Epub 2011 Oct 31.
9
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.MET 改变是 ALK 阳性肺癌中一种反复出现且可采取行动的耐药机制。
Clin Cancer Res. 2020 Jun 1;26(11):2535-2545. doi: 10.1158/1078-0432.CCR-19-3906. Epub 2020 Feb 21.
10
Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.ALK 阳性晚期非小细胞肺癌对克唑替尼的异质性反应和耐药机制。
Thorac Cancer. 2018 Sep;9(9):1093-1103. doi: 10.1111/1759-7714.12791. Epub 2018 Jul 6.

引用本文的文献

1
Partial response to lorlatinib in thoracic inflammatory myofibroblastic tumor harboring complex and rare ALK fusions: a case report.携带复杂罕见ALK融合的胸内炎性肌纤维母细胞瘤对劳拉替尼部分缓解：一例报告
Transl Lung Cancer Res. 2025 Feb 28;14(2):631-638. doi: 10.21037/tlcr-24-963. Epub 2025 Feb 27.
2
Clinical characteristics and treatment management of combined large cell neuroendocrine carcinoma, a subtype of large cell neuroendocrine carcinoma.大细胞神经内分泌癌的一种亚型——联合大细胞神经内分泌癌的临床特征及治疗管理
Front Oncol. 2024 Oct 22;14:1449490. doi: 10.3389/fonc.2024.1449490. eCollection 2024.
3
Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review.
两例病例报告：EML4-ALK重排的大细胞神经内分泌癌及文献综述
Front Oncol. 2023 Nov 1;13:1227980. doi: 10.3389/fonc.2023.1227980. eCollection 2023.
4
New gene signature from the dominant infiltration immune cell type in osteosarcoma predicts overall survival.骨肉瘤中优势浸润免疫细胞类型的新基因特征可预测总生存期。
Sci Rep. 2023 Oct 25;13(1):18271. doi: 10.1038/s41598-023-45566-6.
5
The Unmet Diagnostic and Treatment Needs in Large Cell Neuroendocrine Carcinoma of the Lung.肺癌大细胞神经内分泌癌的未满足诊断和治疗需求。
Curr Oncol. 2023 Jul 27;30(8):7218-7228. doi: 10.3390/curroncol30080523.
6
Case Report: A Pregnant Woman Diagnosed as ALK-Rearrangement Lung Large Cell Neuroendocrine Cancer With Brain Metastasis.病例报告：一名被诊断为ALK重排的肺大细胞神经内分泌癌伴脑转移的孕妇。
Front Oncol. 2022 Feb 25;12:823813. doi: 10.3389/fonc.2022.823813. eCollection 2022.
7
Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.鉴定脑胶质瘤的肿瘤抗原和免疫亚型，用于 mRNA 疫苗的开发。
Front Immunol. 2022 Feb 2;13:773264. doi: 10.3389/fimmu.2022.773264. eCollection 2022.
8
Molecular Pathology of Pulmonary Large Cell Neuroendocrine Carcinoma: Novel Concepts and Treatments.肺大细胞神经内分泌癌的分子病理学：新概念与治疗方法
Front Oncol. 2021 Apr 22;11:671799. doi: 10.3389/fonc.2021.671799. eCollection 2021.